Explore 3 Stock Ideas & Industry Insights Download Free Report
Genus Plc — LSE:GNS closed 2.27% higher on03 September 2026, with the shares at 2,342.00p after a gain of 52.00p on the day.
Hikma Pharmaceuticals Plc — LSE:HIK closed 0.12% higher on03 September 2026, with the shares at 1,617.00p after a gain of 2.00p on the day.
Allergy Therapeutics Plc — LSE:AGY closed 1.48% higher on03 September 2026, with the shares at 5.500p after a gain of 0.080p on the day.
EKF Diagnostics Holdings Plc — LSE:EKF closed 1.69% lower on03 September 2026, with the shares at 24.87p after a decline of 0.43p on the day.
The question for London investors is whether the market has caught up. At 31 March 2026 PureTech held $248.1m of parent-level cash, and its stake in newly listed Seaport Therapeutics was worth roughly $300m at that company's IPO price. Against that sits aMarket Capitalisationof …
Revenue for the six months to 30 June 2026 rose 12.3% at constant currency to £116.7m, grossMarginclimbed 400 basis points to 62.2% and the adjusted EBITDA loss more than halved to £22.1m. With a new chief executive six months into the job, a $20m …
Oxford BioDynamics Plc (LSE:OBD) has spent August 2026 pulling itself back from the edge. On 10 August the 3D-genomics diagnostics group said its cash would run out by early September without a £9.15m placing at just 0.1p a share, a deal handing new investors …
That money matters because in March the FY2025 accounts warned that funds would last only until the second quarter of 2026, a going-concern uncertainty the rights issue has since removed. With a placebo-controlled Phase 2b study, BEXERA, due to start in the second half …
That obscurity is precisely why some investors hunt in this corner of the London Stock Exchange. The immediate question is whether the Ely-based group can turn improving gross margins and growth in the UK and India into a return to profitability, at a moment …
Full-year results are due this month, and the central question is whether the slippage in 340B and enterprise contract revenue is a timing problem, as management insists, or a sign of a tougher market.
We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.
These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.
We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.
These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Download Free Report
Hi! How can we help you today?
Loading…